Your Wegovy second dose: what changes, what to expect, and how to judge readiness

What actually changes between your first and second Wegovy injection

Your first Wegovy pen delivers 0.25mg of semaglutide once a week. That dose is deliberately modest, its job is to let your system adjust to a GLP-1 receptor agonist without triggering intense side effects from the outset. Most people find appetite suppression at 0.25mg is mild or barely noticeable. That is not a flaw in the medicine; it is by design.

The second dose (0.5mg) roughly doubles the amount of semaglutide your body receives each week. For many people this is when the medicine starts to feel like it is doing something: hunger between meals drops, portion sizes feel less urgent, and the urge to snack tends to ease. The Wegovy overview goes into the pharmacology in more detail, but in practical terms the 0.5mg level is where the titration schedule shifts from preparation to treatment.

There is a common misconception worth addressing gently: some people assume that if they felt little at 0.25mg, the medicine is not working for them. That is rarely the case. The starter level simply is not designed to produce strong effects. Reaching the second dose is the more meaningful test.

The Wegovy dosing schedule describes how each level relates to the next, and what the full titration path looks like across the five doses.

Deciding whether you are ready to move up

Timing matters here. The standard interval before taking your second Wegovy dose is approximately four weeks from your first injection, that is the schedule set out in the licensed dosing pathway and reviewed by your prescriber. But four weeks is a minimum guide, not a countdown you are obliged to hit.

The factors your prescriber will weigh include how you have tolerated 0.25mg, whether any gastrointestinal symptoms have settled, and whether there are any clinical reasons to extend your time at the starter dose. A person who spent most of week three feeling nauseated may be better served staying at 0.25mg a little longer. That is not a setback; it is the titration working as intended.

You should not adjust your dose timing yourself. If you are unsure whether you are ready to move to 0.5mg, contact your prescribing team. Our frequently asked questions cover some of the practical queries around dose timing, and our support team is available seven days a week for patients under our care.

For a closer look at the practical steps around taking your next injection, the guide to taking your second Wegovy dose covers technique, timing and what to prepare.

Side effects to be aware of at the 0.5mg level

Moving to the second dose is one of the more common moments for side effects to surface or intensify. The most frequently reported effects across Wegovy's clinical programme are gastrointestinal: nausea, loose stools, constipation, indigestion and belching. Tiredness and headache appear less often but are also documented. As the NHS guidance on semaglutide notes, these effects tend to be at their most noticeable shortly after a dose change and usually ease within a few days to two weeks as the body adapts.

Eating smaller portions, staying well hydrated and avoiding very high-fat meals can help during this adjustment window. Most people find symptoms are manageable at 0.5mg even if 0.25mg was entirely symptom-free, the step up is real, but it is gradual by design.

If you experience severe, persistent abdominal pain that radiates towards your back, seek medical attention promptly. The MHRA has flagged acute pancreatitis as a known but infrequent risk with GLP-1 medicines, and this is the symptom pattern to take seriously. A full picture of what to watch for at every dose is set out on the second-dose side effects page.

Reporting any unexpected or severe effects is straightforward via the MHRA Yellow Card scheme, which is open to patients as well as healthcare professionals.

Where to go next on the titration ladder

Assuming 0.5mg is well tolerated, the path continues upward through 1.0mg, 1.7mg and ultimately 2.4mg, with Wegovy's 7.2mg dose now also approved by the MHRA for eligible adults with obesity, extending the ceiling further. Each step follows the same four-weekly rhythm, always subject to clinical review. The full Wegovy dose guide maps the entire schedule and what the evidence suggests at each level.

One practical note: some people reach a dose where they feel well and their weight loss is progressing steadily, and ask whether they need to keep titrating upward. That question is worth raising with your prescriber rather than deciding alone. The Wegovy full dose page explores what the evidence shows at maintenance level and how that decision is usually approached clinically.

If you are exploring Wegovy as a private treatment option, see the treatment options page to check your eligibility and start a free consultation with our prescribing team.